Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570471 | 1.00 | SCN9A (0.38) | SCN9ACA12CA1CA2CA9 | |
| SCHEMBL7281508 | 0.84 | SCN9A (0.39) | SCN9AFPR2 | |
| Hydrochloric Acid SCHEMBL7271191 | 0.83 | FPR2 (0.38) | SCN9ACA14FPR2ALDH1A1KDM4E | |
| SCHEMBL2744048 | 0.77 | — | — | |
| SCHEMBL31301122 | 0.75 | HAO1 (0.39) | SCN9ACA12CA1CA2CA9 | |
| SCHEMBL7487709 | 0.73 | — | — | |
| SCHEMBL3423922 | 0.73 | ALDH1A1 (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL7487716 | 0.73 | — | — | |
| SCHEMBL5314557 | 0.72 | — | — | |
| SCHEMBL18263906 | 0.71 | SCN9A (0.35) | SCN9ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647500-A9 | METHOD FOR DIRECTLY PREPARING L-GLUFOSINATE FROM L-HOMOSERINE | Hunan Lier Biotech Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| EP-4647500-A1 | METHOD FOR DIRECTLY PREPARING L-GLUFOSINATE FROM L-HOMOSERINE | Hunan Lier Biotech Co., Ltd. (CN) | 2025-11-12 | — | — | EP | claimed |
| EP-3912641-B1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | SEAGEN INC (US) | 2024-11-06 | — | — | EP | claimed |
| EP-3107557-B1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2021-06-09 | — | — | EP | claimed |
| CN-106029083-B | Hydrophilic antibody-drug conjugates | 西雅图基因公司 | 2020-02-07 | — | — | CN | claimed |
| EP-1015007-A1 | ANALOGS OF PEPTIDE YY AND USES THEREOF | THE UNIVERSITY OF CINCINNATI (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998020885-A1 | ANALOGS OF PEPTIDE YY AND USES THEREOF | UNIVERSITY OF CINCINNATI (US) | 1998-05-22 | — | — | WO | claimed |
| EP-0707490-A1 | NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS | UNIVERSITY OF CINCINNATI (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995000161-A1 | NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS | UNIVERSITY OF CINCINNATI (US) | 1995-01-05 | — | — | WO | claimed |
| EP-4647500-A9 | METHOD FOR DIRECTLY PREPARING L-GLUFOSINATE FROM L-HOMOSERINE | Hunan Lier Biotech Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| EP-4647500-A1 | METHOD FOR DIRECTLY PREPARING L-GLUFOSINATE FROM L-HOMOSERINE | Hunan Lier Biotech Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-11566047-B2 | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) | 2023-01-31 | — | — | US | disclosed |
| WO-2022080385-A1 | PEPTIDE, AND MODIFICATION OF ANTIBODY WITH PEPTIDE | 国立大学法人京都大学 | 2022-04-21 | — | — | WO | disclosed |
| CN-106029083-B | Hydrophilic antibody-drug conjugates | 西雅图基因公司 | 2020-02-07 | — | — | CN | disclosed |
| US-5627283-A | ANTITHROMBIN COMPOUNDS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-05-06 | — | — | US | disclosed |
| WO-1996014854-A1 | TREATMENT OF PANCREATIC TUMORS WITH PEPTIDE YY AND ANALOGS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0707490-A1 | NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS | UNIVERSITY OF CINCINNATI (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0692971-A1 | ANALOGS OF PEPTIDE YY AND USES THEREOF | UNIVERSITY OF CINCINNATI (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5457114-A | Antithrombin; antithrombotic, enzyme resistance, tolerability | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1995-10-10 | — | — | US | disclosed |
| WO-1995000161-A1 | NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS | UNIVERSITY OF CINCINNATI (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566047-B2 | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof | MYOF, MSTN, VIP | SCN9A 1965/4885CA12 730/4885CA1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.